---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-124393"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:59:42.225522+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD

## Summary
- Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.
- Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.
- Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.
- Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.
- (Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS.

## SEC filing metadata
- accession: 0001193125-26-124393
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/0001193125-26-124393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000119312526124393/atos-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-124393
- JSON: https://secwatch.observer/filing/0001193125-26-124393.json
- Plain text: https://secwatch.observer/filing/0001193125-26-124393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.